Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Uveal Melanoma 1Rectal Neoplasms 1

Interventions

Cyclophosphamide 1499Cisplatin 1434Paclitaxel 1339Radiotherapy 1310Carboplatin 1266Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 697Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Receptor-Like Protein Tyrosine Phosphatases, Class 2 × Clear all
NCT03574493 2025-02-12

RESET

Institut du Cancer de Montpellier - Val d'Aurelle

Completed
1,098 enrolled
Gastrointestinal

Rectal Neoplasms

NCT01252251 2017-08-01

RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
14 enrolled 12 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡